GSK plc American (GSK) carries a Roarable Rating of D+ (Sell) with 57/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, GSK plc American (NYSE: GSK) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $49.51 (+1.71% 1D, market cap $98.47B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, GSK ranks #205 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GSK carries a Roarable D+ (57/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, SNY (Sanofi ADS) holds a C- grade (59/100 RQD, P/E 32.8x, ROIC 9.9%, cap $105.19B) and REGN (Regeneron Pharmaceuticals Inc.) posts a B+ grade (80/100 RQD, P/E 18.7x, ROIC 9.4%, cap $84.30B). Among the 5-stock peer group, BMY leads on earnings multiple (17.8x) while VRTX leads on capital efficiency (20.0% ROIC).
For GSK plc American (GSK), key quantitative strengths include Clean SEC annual filing review with no major hidden accounting time-bombs. and sector rank #205 in Health Care, while primary risk factors center on Sensitive to high interest rates and tighter Federal Reserve market liquidity. and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.74 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9
SEC XBRL Trailing 12 Months: 15.8% FCF Margin ($2.18B FCF) & 52% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)
Even with a 57/100 (D+) score, GSK faces multiple-compression risk if 32.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Sensitive to high interest rates and tighter Federal Reserve market liquidity.
Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($49.30) or 200D SMA ($52.34) invalidates the momentum regime and cuts Target Base ($49.29) toward Bear Floor ($38.45).
GSK plc American (GSK) advanced +1.71% to $49.51, trading at 23% of its 52-week range ($45.81 – $61.7). Stretched risk/reward at 33x P/E (10% return on capital) under elevated 10-year interest-rate pressure.
Kalkine Media report covering GSK plc American (GSK) market action, institutional positioning, and fundamental catalysts.
Five presentations will highlight new analyses of linerixibat in cholestatic pruritus associated with primary biliary cholangitis, including an oral presentation and four posters from the Phase 3 GLISTEN study and real-w
GSK (LSE:GSK) received accelerated FDA approval for Jemperli as the first immunotherapy for certain rectal cancer patients. The approval covers a genetically defined group of rectal cancer cases where Jemperli offers a n
Gilead Sciences had a strong Q3, while successfully shifting its R&D focus from HIV to the immunology market. Read why GILD stock is a buy.
GSK stock remains a Buy despite Q3 misses, with Specialty Medicines growth, pipeline momentum, valuation upside, and key risks to watch. See more here.
Jefferies analyst Michael Leuchten downgrades GSK (NYSE:GSK) from Buy to Hold and lowers the price target from $67.4 to $55.9.
GSK's Specialty Medicines growth, deep pipeline and dividend offer a compelling case against MRNA's oncology potential and premium valuation.
PARMA, Italy, October 29, 2026--Chiesi, the international research-focused biopharmaceutical group, today announced the appointment of Paolo Paoletti, M.D. to its Board of Directors, effective as of today. Paoletti is an
GSK (LSE:GSK) has released third quarter figures that present a mixed picture. Sales reached £8,887 million, while net income declined to £1,543 million compared with £2,013 million a year earlier. The latest figures lan
Genmab scores a ‘hat trick’ with positive data for its experimental cancer drug, petosemtamab, Jefferies says.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +8.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on GSK today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for GSK. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, GSK plc American (GSK) ranks #205 by composite RQD confidence (57/100, grade D+) and #24 by equity capitalization ($98.47B). Within this direct 5-issuer industry benchmark cohort, BMY leads on earnings valuation at 17.8x trailing P/E, while VRTX leads on capital efficiency and profitability with 20.0% ROIC and 86.2% gross margin. REGN currently holds the highest overall quantitative score in the immediate peer group at 80/100 (B+) compared with GSK at 57/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| GSK
ACTIVE
GSK plc American | D+ | 57/100 | 32.8x | — | 9.9% | +1.71% | $98.47B | Benchmark Subject |
| SNY Sanofi ADS | C- | 59/100 | 32.8x | — | 9.9% | +2.81% | $105.19B | /sny-vs-gsk → |
| REGN Regeneron Pharmaceuticals Inc. | B+ | 80/100 | 18.7x | — | 9.4% | +13.33% | $84.30B | /regn-vs-gsk → |
| BMY Bristol-Myers Squibb Company | C | 63/100 | 17.8x | 71.1% | 13.3% | +1.78% | $125.40B | /bmy-vs-gsk → |
| VRTX Vertex Pharmaceuticals Incorporated | B+ | 80/100 | 34.6x | 86.2% | 20.0% | +3.50% | $136.87B | /vrtx-vs-gsk → |
GSK plc American (GSK) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $98.47B, trailing P/E of 32.8x, forward P/E of 30.5x, and EV/EBITDA of 21.0x. Operating profitability registers a gross margin of —, operating margin of 13.9%, net profit margin of 10.9%, ROIC of 9.9%, and free cash flow yield of 2.21%, alongside an Altman Z-Score of 3.74 and Piotroski F-Score of 8/9.
As of 2026-11-02, GSK plc American (NYSE: GSK) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 57/100 at a spot price of $49.51 (+1.71% 1D, market cap $98.47B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, GSK ranks #205 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GSK carries a Roarable D+ (57/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, SNY (Sanofi ADS) holds a C- grade (59/100 RQD, P/E 32.8x, ROIC 9.9%, cap $105.19B) and REGN (Regeneron Pharmaceuticals Inc.) posts a B+ grade (80/100 RQD, P/E 18.7x, ROIC 9.4%, cap $84.30B). Among the 5-stock peer group, BMY leads on earnings multiple (17.8x) while VRTX leads on capital efficiency (20.0% ROIC).
For GSK plc American (GSK), key quantitative strengths include Clean SEC annual filing review with no major hidden accounting time-bombs. and sector rank #205 in Health Care, while primary risk factors center on Sensitive to high interest rates and tighter Federal Reserve market liquidity. and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
GSK last traded at $49.51 (+1.71% on volume of 4,767,316 shares), positioning the stock +0.43% above its 50-day simple moving average ($49.30) and -5.41% below its 200-day simple moving average ($52.34). Across its 52-week range of $45.81 to $61.70, GSK sits at the 23.3% percentile with a 14-day RSI of 46.8 (NEUTRAL RANGE) and an implied next-earnings move of ±3.7% ($47.68 to $51.34).
Why GSK Stock advanced +1.71% Today — RQD Quant Desk Flash. Stretched risk/reward at 33x P/E (10% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, GSK scores 57 out of 100, a D+ grade labeled "Roarable Sell — Weak Fundamentals / Trim." The five pillars are:
Implications: The upside case rests on earnings durability and balance-sheet strength. The valuation tradeoff is significant: at a P/E (TTM) of 32.8 and forward P/E of 30.5, the stock is priced at a premium relative to its modest FCF yield, so returns depend on execution. The rating's overall verdict reflects weak cash-return and flow signals against a solid balance sheet.
GSK plc American is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry, per the company profile. Its market capitalization is $98.5B. The source data does not detail its products, customers, or revenue model. Per the profile, it trades on the NYSE under the ticker GSK.
The news wire contains one item: a Kalkine Media report, dated 1h ago per the feed, headlined around directors and PDMRs completing share acquisitions via dividend reinvestment on 8-9 October 2026. Its light indicator is YELLOW and impact label is MARKET WIRE. The summary is generic and does not specify the size or significance of the transactions. Per the Butterfly Supply-Chain Graph, no supply-chain links or proprietary signals are present. Key watch items from the available data are the 52-week range ($45.81 - $61.7) relative to the current price and the stock's modest daily move (-0.12%).
Per the Butterfly Supply-Chain Graph, the supply chain is NONE and there are no butterfly links. Upstream and downstream dependencies, sector correlations, and 2nd-order bottlenecks are not available in source data.
Real-time company headlines, analyst actions, and sector developments for GSK plc American (GSK) • Click "Debate This Headline" to argue it in the Roar Pit below
Kalkine Media report covering GSK plc American (GSK) market action, institutional positioning, and fundamental catalysts.
Five presentations will highlight new analyses of linerixibat in cholestatic pruritus associated with primary biliary cholangitis, including an oral presentation and four posters from the Phase 3 GLISTEN study and real-w
GSK (LSE:GSK) received accelerated FDA approval for Jemperli as the first immunotherapy for certain rectal cancer patients. The approval covers a genetically defined group of rectal cancer cases where Jemperli offers a n
Gilead Sciences had a strong Q3, while successfully shifting its R&D focus from HIV to the immunology market. Read why GILD stock is a buy.
GSK stock remains a Buy despite Q3 misses, with Specialty Medicines growth, pipeline momentum, valuation upside, and key risks to watch. See more here.
Jefferies analyst Michael Leuchten downgrades GSK (NYSE:GSK) from Buy to Hold and lowers the price target from $67.4 to $55.9.
GSK's Specialty Medicines growth, deep pipeline and dividend offer a compelling case against MRNA's oncology potential and premium valuation.
PARMA, Italy, October 29, 2026--Chiesi, the international research-focused biopharmaceutical group, today announced the appointment of Paolo Paoletti, M.D. to its Board of Directors, effective as of today. Paoletti is an
Welcome to the GSK (GSK plc American) Roar Pit. Current RQD Composite is 57/100 (Roarable Sell — Weak Fundamentals / Trim) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on valuation multiple compression (32.8x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on GSK, but look at what you are paying: 32.8x trailing P/E with tightening sector spreads. Unless GSK plc American expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on GSK, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $48.68 (52-wk range $45.81 - $61.70), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).